middle.news
How Is PYC Therapeutics Advancing Four RNA Drug Candidates with $121M Cash?
9:00am on Friday 23rd of January, 2026 AEDT
•
Biotechnology
Read Story
How Is PYC Therapeutics Advancing Four RNA Drug Candidates with $121M Cash?
9:00am on Friday 23rd of January, 2026 AEDT
Key Points
Completion of safety review in healthy volunteers for Polycystic Kidney Disease (PKD) program
Initiation of global repeat dose study for Autosomal Dominant Optic Atrophy (ADOA)
Sustained vision improvement data presented for Retinitis Pigmentosa type 11 (RP11)
Preclinical data supports progression of Phelan-McDermid Syndrome (PMS) candidate to clinical trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Pyc Therapeutics (ASX:PYC)
OPEN ARTICLE